BioCentury
ARTICLE | Company News

CIRM funding news

March 10, 2017 12:36 AM UTC

CIRM awarded $32.6 million in grants to fund clinical trials and R&D. Caladrius will receive up to $12.2 million for its ongoing Phase II trial of autologous T regulatory cells (CLBS03) to treat recent-onset Type I diabetes. Interim data from the trial are expected by year end. CLBS03 is a polyclonal T regulatory cell therapy.

CIRM also granted $6.2 million to Cedars-Sinai to evaluate re-engineered astrocytes in a Phase I trial to treat amyotrophic lateral sclerosis (ALS) and $11.9 million to St. Jude to evaluate genetically modified blood stem cells in a Phase I/II trial to treat x-linked severe combined immunodeficiency disorder (SCID). ...